A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

Diagnostic Microbiology and Infectious Disease

Volumn 63, Issue 2, 2009, Pages 233-236

  Diekema, Daniel J ^a   Messer, Shawn A ^a   Hollis, Richard J ^a   Boyken, Linda ^a   Tendolkar, Shailesh ^a   Kroeger, Jennifer ^a   Jones, Ronald N ^b   Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Jones Microbiology Institute   (United States)

Author keywords

Candida; Surveillance; Voriconazole

Indexed keywords

VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANDIDA; GEOGRAPHIC DISTRIBUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PYRIMIDINES; TRIAZOLES; WORLD HEALTH;

EID: 58149512867     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.11.001     Document Type: Article

References (19)

1. Alexander B.D., Schell W.A., Miller J.L., Long G.D., and Perfect J.R. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80 (2005) 868-871
2. Arendup M.C., Fuursted K., Gahrn-Hansen B., Schonheyder H.C., Knudson J.D., Jensen I.M., Bruun B., Christensen J.J., and Johansen H.K. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14 (2008) 487-494
3. Borg-von Zepelin M., Kunz L., Ruchel R., Reichard U., Weig M., and Groh U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004-August 2005. J. Antimicrob. Chemother. 60 (2007) 424-428
4. Gonzalez G.M., Elizondo M., and Ayala J. Trends in species distribution and susceptibility to seven antifungal agents of bloodstream isolates of Candida in Monterrey, Mexico. Results of a 3-year surveillance study. J. Clin. Microbiol. (2008) [electronic publication ahead of print]
5. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347 (2002) 408-415
6. Imhof A., Balajee S.A., Fredricks D.N., Englund J.A., and Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39 (2004) 743-746
7. Johnson L.B., and Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36 (2003) 630-637
8. Kuhlberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., Cleary J.D., Rubinstein E., Church L.W., Brown J.M., Schlamm H.T., Oborsha I.T., Hilton F., and Hodges M.R. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in nonneutropenic patients: a randomized non-inferiority trial. Lancet 366 (2005) 1435-1442
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 2nd ed. (2002), National Committee for Clinical Laboratory Standards, Wayne (PA) M27-A2
10. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47 (2003) 3149-3154
11. Perfect J.D., Marr K.A., Walsh T.J., Greenberg R.N., DuPoint B., de la Torre-Cisneros J., Just-Nubling G., Schlamm H.T., Lutsar I., Espinel-Ingroff A., and Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36 (2003) 1122-1131
12. Pfaller M.A., and Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40 (2002) 3551-3557
13. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., and Diekema D.J. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46 (2002) 1723-1727
14. Pfaller M.A., Messer S.A., Boyken L., Hollis R.J., Rice C., Tendolkar S., and Diekema D.J. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and C. neoformans collected during 2001-2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48 (2004) 201-205
15. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., Chaturvedi V., Ghannoum M.A., Odds F.C., Rinaldi M.G., Sheehan D.J., Troke P., Walsh T.J., and Warnock D.W. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 44 (2006) 819-826
16. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Meis J.F., Gould I.M., Fu W., Colombo A.L., Rodriguez-Noriega E., and and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997-2005: an 8.5 year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45 (2007) 1735-1745
17. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., and Diekema D.J. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J. Clin. Microbiol. 45 (2007) 70-75
18. Quindos G., Sanchez-Vargas L.O., Villar-Vidal M., Eraso E., Alkorta M., and Hernandez-Almaraz J.L. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int. J. Antimicrob. Agents Chemother. 31 (2008) 266-271
19. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P., and and the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35 (2002) 627-630